Adverum Biotechnologies Announces 3-Year Efficacy and Safety

Adverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023

Adverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023

tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

United Kingdom , United States , California , San Francisco , American , Carl Regillo , Carld Regillo , Laurent Fischer , American Academy Of Ophthalmology , Drug Administration , Nasdaq , Retina Service At Wills Eye Hospital , European Medicines Agency , Adverum Biotechnologies Inc , Healthcare Products Regulatory Agency , Exchange Commission , Clinical Program Milestones , Biotechnologies Announces , Year Efficacy , Safety Results , Retina Subspecialty Day , American Academy , Extension Data , Gene Therapy , Preliminary Data , Year Results From , Protein Data Highlights , Baseline Characteristics , Clinical Program , Program Milestones , Retina Service , Wills Eye Hospital , Fast Track , Innovation Passport , Private Securities Litigation Reform Act , Quarterly Report ,